Epigenetics-related genes in prostate cancer: Expression profile in prostate cancer tissues, androgen-sensitive and -insensitive cell lines

International Journal of Molecular Medicine

Volumn 31, Issue 1, 2013, Pages 21-25

  Adler, David ^a   Lindstrot, Andreas ^a   Ochsenfahrt, Jacqueline ^a   Fuchs, Kerstin ^a   Wernert, Nicolas ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Cell lines; Epigenetics; Prostate cancer

Indexed keywords

ADENOSINE DEAMINASE; ANDROGEN; DICER; DICER 1; DIGEORGE SYNDROME CRITICAL REGION PROTEIN 8; GLOMULIN; HISTONE LINKER H1 DOMAIN; PIWI LIKE 2; PIWI PROTEIN; PROTEIN; RIBONUCLEASE III; RNA BINDING MOTIF PROTEIN 3; SMAD1 PROTEIN; SOMATOMEDIN B; TRINUCLEOTIDE REPEAT CONTAINING 6A; TRIPARTITE MOTIF CONTAINING 27; TUDOR DOMAIN CONTAINING 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENOME; HUMAN; HUMAN TISSUE; MALE; METASTASIS; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRINUCLEOTIDE REPEAT; TUMOR DIFFERENTIATION; UPREGULATION;

EID: 84873190598     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1173     Document Type: Article

References (24)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Draisma G, Etzioni R, Tsodikov A, et al: Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 101: 374-383, 2009.
3. Park JY: Promoter hypermethylation in prostate cancer. Cancer Control 17: 245-255, 2010.
4. Wu JN and Dall'Era MA: Active surveillance for localized prostate cancer - current practices and recommendations. Sci World J 10: 2352-2361, 2010.
5. Schulz WA and Hoffmann MJ: Epigenetic mechanisms in the biology of prostate cancer. Semin Cancer Biol 19: 172-180, 2009.
6. Arora R, Koch MO, Eble JN, Ulbright TM, Li L and Cheng L: Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 100: 2362-2366, 2004.
7. Ruijter ET, Van de Kaa CA, Schalken JA, Debruyne FM and Ruiter DJ: Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol 180: 295-299, 1996.
8. Rennie PS and Nelson CC: Epigenetic mechanisms for progression of prostate cancer. Cancer Metastasis Rev 17: 401-409, 1998.
9. Iacobuzio-Donahue CA: Epigenetic changes in cancer. Annu Rev Pathol 4: 229-249, 2009.
10. Perry AS, Watson RW, Lawler M and Hollywood D: The epigenome as a therapeutic target in prostate cancer. Nat Rev Urol 7: 668-680, 2010.
11. Joshua AM, Evans A, Van der Kwast T, et al: Prostatic preneoplasia and beyond. Biochim Biophys Acta 1785: 156-181, 2008.
12. Wellmann A, Wollscheid V, Lu H, et al: Analysis of microdissected prostate tissue with ProteinChip arrays - a way to new insights into carcinogenesis and to diagnostic tools. Int J Mol Med 9: 341-347, 2002.
13. Okuducu AF, Janzen V, Hahne JC, Ko Y and Wernert N: Influence of histochemical stains on quantitative gene expression analysis after laser-assisted microdissection. Int J Mol Med 11: 449-453, 2003.
14. Okuducu AF, Hahne JC, Von Deimling A and Wernert N: Laser-assisted microdissection, techniques and applications in pathology (Review). Int J Mol Med 15: 763-769, 2005.
15. Chiosea S, Jelezcova E, Chandran U, et al: Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol 169: 1812-1820, 2006.
16. Faber C, Horst D, Hlubek F and Kirchner T: Overexpression of Dicer predicts poor survival in colorectal cancer. Eur J Cancer 47: 1414-1419, 2011.
17. Ribarska T, Bastian KM, Koch A and Schulz WA: Specific changes in the expression of imprinted genes in prostate cancer-implications for cancer progression and epigenetic regulation. Asian J Androl 14: 436-450, 2012.
18. Yoo NJ, Hur SY, Kim MS, Lee JY and Lee SH: Immunohistochemical analysis of RNA-induced silencing complex-related proteins AGO2 and TNRC6A in prostate and esophageal cancers. APMIS 118: 271-276, 2010.
19. Jonsson L, Gaber A, Ulmert D, Uhlen M, Bjartell A and Jirstrom K: High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression. Diagn Pathol 6: 91, 2011.
20. Lee JH, Schutte D, Wulf G, et al: Stem-cell protein Piwil2 is widely expressed in tumors and inhibits apoptosis through activation of Stat3/Bcl-XL pathway. Hum Mol Genet 15: 201-211, 2006.
21. Yoon H, Lee H, Kim HJ, et al: Tudor domain-containing protein 4 as a potential cancer/testis antigen in liver cancer. Tohoku J Exp Med 224: 41-46, 2011.
22. Paz N, Levanon EY, Amariglio N, et al: Altered adenosine-to-inosine RNA editing in human cancer. Genome Res 17: 1586-1595, 2007.
23. Barr I, Smith AT, Senturia R, et al: DiGeorge critical region 8 (DGCR8) is a double-cysteine-ligated heme protein. J Biol Chem 286: 16716-16725, 2011.
24. Gregory RI and Shiekhattar R: MicroRNA biogenesis and cancer. Cancer Res 65: 3509-3512, 2005.